NYSE:MRKPharmaceuticals
Merck (MRK) Gets Fresh KEYTRUDA Momentum In EU Testing And Biliary Cancer Trials
Merck (NYSE:MRK) is seeing new clinical progress for its KEYTRUDA franchise in Europe and in hard to treat cancers.
Agilent received EU approval to use its PD-L1 IHC 22C3 pharmDx test as a companion diagnostic to identify patients eligible for KEYTRUDA in additional gynecologic cancers.
Phanes Therapeutics expanded its clinical trial collaboration with Merck to study KEYTRUDA in combination regimens for biliary tract cancer.
These updates highlight how Merck is continuing to develop...